Immunizations - pneumococcal
Exam Tips
- State clearly that IPD means pneumococcus isolated from a normally sterile site (for example blood or CSF).
- In UK exams, remember: routine PPV23 is a single dose at age 65+, with 5-yearly boosters only in asplenia/splenic dysfunction or chronic renal disease.
- Children under 2 years respond poorly to PPV23; they need PCV-based schedules first.
- If vaccine history is uncertain in an at-risk child, assume unvaccinated and give age-appropriate catch-up.
- Differentiate conjugate vs polysaccharide vaccines: PCV gives better immunological memory and reduces carriage; PPV23 gives broader serotype coverage but wanes.
- Visual learning aid: see Green Book pneumococcal schedule tables/flowcharts for age- and risk-stratified dosing logic.
Definition
Pneumococcal disease comprises infections caused by the encapsulated Gram-positive diplococcus Streptococcus pneumoniae, ranging from mucosal disease (such as otitis media, sinusitis, and non-bacteraemic pneumonia) to invasive pneumococcal disease (IPD). IPD is defined by isolation of S. pneumoniae from a normally sterile site (for example blood or CSF), and carries substantially higher risks of sepsis, meningitis, and death, particularly at the extremes of age and in immunocompromised people.
Pathophysiology
S. pneumoniae colonises the nasopharynx and spreads via respiratory droplets/direct secretion contact, with short incubation (often around 1-3 days). Disease follows failure of local and systemic host defences: the polysaccharide capsule inhibits phagocytosis, enabling invasion from upper airway mucosa into lung parenchyma or bloodstream. Conjugate vaccines (PCV13/PCV15) link capsular polysaccharide to a protein carrier, generating T-cell-dependent immune memory and reducing carriage (therefore contributing to herd protection), while PPV23 induces a mainly T-cell-independent response that broadens serotype coverage but is less immunogenic in children under 2 years and wanes over time.
Risk Factors
- Age under 2 years
- Age 65 years or over
- Asplenia or splenic dysfunction (including sickle cell disease, coeliac-associated hyposplenism)
- Chronic respiratory disease (COPD, bronchiectasis, cystic fibrosis, interstitial lung disease, pneumoconiosis, aspiration risk states)
- Asthma requiring prolonged high-dose oral corticosteroids (prednisolone equivalent >=20 mg/day for >1 month in adults; >=1 mg/kg/day if child <20 kg)
- Chronic heart disease (ischaemic heart disease, heart failure, congenital heart disease)
- Advanced chronic kidney disease, nephrotic syndrome, dialysis, renal transplant
- Chronic liver disease (cirrhosis, chronic hepatitis, biliary atresia)
- Diabetes treated with insulin or oral hypoglycaemics
- Immunosuppression (chemotherapy, HIV at any stage, bone marrow transplant, complement disorders, multiple myeloma, inherited immune defects)
- Cochlear implant
- Cerebrospinal fluid leak (including post-trauma/neurosurgery)
- Occupational metal fume exposure (for example welding)
Clinical Features
Symptoms
- Fever, rigors, malaise
- Acute cough with purulent sputum and pleuritic chest pain
- Dyspnoea
- Headache, photophobia, neck stiffness (meningeal involvement)
- Ear pain/discharge or sinus pain in non-invasive disease
- Confusion, reduced oral intake, functional decline in older adults
Signs
- Pyrexia, tachycardia, tachypnoea, hypoxia
- Focal chest signs (bronchial breathing, crackles, dullness to percussion) in lobar pneumonia
- Hypotension or poor perfusion in sepsis
- Meningism, altered consciousness, focal neurology in pneumococcal meningitis
- Signs of dehydration or delirium in frail patients
Investigations
Management
Lifestyle Modifications
- Opportunistic vaccine status checks in primary care, chronic disease reviews, antenatal/postnatal contacts, and hospital discharge planning
- Smoking cessation and optimisation of chronic cardiorespiratory disease to reduce pneumococcal morbidity
- Occupational risk reduction for metal fume exposure (for example welders: respiratory protection and vaccination)
- Safety-netting: urgent review for red flags of invasive infection (confusion, hypotension, meningism, persistent hypoxia)
Pharmacological Treatment
Pneumococcal conjugate vaccines (active immunisation)
- Prevenar 13 (PCV13) 0.5 mL IM per dose
- Vaxneuvance (PCV15) 0.5 mL IM per dose
Routine infant programme uses PCV from 2 months onward (UK schedule includes doses in infancy with booster at/after 1 year). For at-risk children, additional PCV doses depend on age and risk severity; severe immunocompromise/asplenia/complement disorders need enhanced schedules with >=8-week minimum intervals. Premature infants are vaccinated by chronological age. Main contraindication: previous anaphylaxis to a vaccine dose/component; defer in acute severe febrile illness.
Pneumococcal polysaccharide vaccine
- Pneumovax 23 (PPV23) 0.5 mL IM or deep SC as a single dose
Offer routinely to all adults >=65 years (single dose). Re-immunise every 5 years only for asplenia/splenic dysfunction or chronic renal disease. In at-risk children >=2 years, give PPV23 at least 8 weeks after last PCV dose. Not effective in children <2 years, so do not use in this age group. If immunisation history is unreliable, treat as unvaccinated and restart age-appropriate schedule.
Treatment of established pneumococcal infection (not prophylaxis)
- Amoxicillin 500 mg to 1 g orally three times daily (typical adult CAP first-line, severity-guided)
- Benzylpenicillin IV (dose by severity/local protocol) for severe suspected pneumococcal sepsis/meningitis pending cultures
- Ceftriaxone IV (dose by indication/protocol) when meningitis or severe beta-lactam resistance risk is considered
Use local antimicrobial guidance and culture results to narrow therapy. In suspected bacterial meningitis, give urgent empiric IV antibiotics without delay. Check penicillin/beta-lactam allergy history and renal function; adjust doses in renal impairment where required.
Complications
- Invasive pneumococcal disease (bacteraemia, meningitis)
- Septic shock and multi-organ dysfunction
- Parapneumonic effusion or empyema
- Respiratory failure requiring ventilatory support
- Neurological sequelae after meningitis (hearing loss, cognitive impairment, focal deficits)
- Death, especially in older adults and immunocompromised patients
Prognosis
Population prognosis has improved with conjugate vaccination and indirect herd effects, but outcomes remain age- and comorbidity-dependent. Older adults, asplenic patients, and those with major immunosuppression have higher risks of severe IPD, recurrent infection, and mortality; protection from PPV23 can wane after around 5 years, informing revaccination in selected high-risk groups.
Sources & References
✅NICE Guidelines(1)
- Immunizations - pneumococcal[overview]